RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:INTERESTING ARTICLE RE LIPID MANAGEMENT , DOSING START Hi Sanfran. Your posts are always excellent because they explore the possibiities.
(is there a spell check on this site?).
However, I really do wonder about the valuation assumptions regarding the IPO value of Zenith being dragged down by the negative "brand equity" of rvx-208 - perceived broken promises. Well, the only broken promise (or hope for all) was the .6% plaque regression - apparently an ill conceived end point.
From what I understand from biotech (he or she) did not agree with this criteria from the beginning. We know the MACE has to be replicated and if it replicates the impact on valuation is huge.
So now, on rvx-208 we have great scientific results...but the RVX brand reputation remains tarnished.
We all seem to assume that the near miss (remember it achieved a .4% regression) drags down Zenith. I recognize that the boards and management are the same between RVX and Zenith.
However, epigenetics and 208 are 2 separate pursuits. If Zenith can get some scientific wins out there (as they seem to have done in the lab) there should be the possibility to manage a successful IPO or 2 or 3 or 4.
For example, there could be the options of separating the brands completely. If RVX is a drag on Zentih there should be a complete perceptual separation. Websites should not be linked. They should completely unlink.
Zenith could quickly develop an independent positioning. A new board could be appointed. New scientific faces could be put in place.
Obviously, these are very talented scientific people and their brand reputations should be maximized.
Challenge the assumptions!
Cheers
Toinv :)